# A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

> **NCT07222709** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 48 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ABBV-1042
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07222709
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07222709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07222709, "A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07222709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*